Connect Biopharma announced positive Phase 2 trial results for rademikibart, a potential new biologic treatment for moderate-to-severe uncontrolled asthma....

BridgeBio Pharma presented data from a subgroup analysis of its Phase 3 ATTRibute-CM trial, demonstrating acoramidis significantly improved clinical...

Tenaya Therapeutics announced interim Phase 1b/2 clinical trial data for TN-201, a gene therapy for •MYBPC3•-associated hypertrophic cardiomyopathy (HCM)....

JenaValve Technology announced positive results from an expanded 500-patient cohort in the ALIGN-AR Pivotal Trial, evaluating the Trilogy Transcatheter...

NeOnc Technologies Holdings, Inc. has received Rare Pediatric Disease Designation (RPDD) from the FDA for its perillyl alcohol (NEO100™)...

CorVista Health presented preliminary data at the American College of Cardiology’s Annual Scientific Session (ACC.25) demonstrating the potential of...

Treace Medical Concepts announced positive interim data from three clinical studies of its bunion and midfoot correction surgical procedures...

Tremfya (guselkumab), Johnson & Johnson’s IL-23 inhibitor, has received FDA approval for Crohn’s diseaseCrohn’s disease, adding to the existing...

Silexion Therapeutics Corp. (NASDAQ: SLXN) is expanding the development plan for its next-generation siRNA candidate, SIL204, to treat KRAS-driven...

Corbus Pharmaceuticals has dosed the first subject in a Phase 1 trial for CRB-913, an investigational drug for obesity....